172 related articles for article (PubMed ID: 34253867)
1. Major pathologic response assessment and clinical significance of metastatic lymph nodes after neoadjuvant therapy for non-small cell lung cancer.
Liu X; Sun W; Wu J; Feng Y; Mao L; Chen M; Yang X; Wang H; Chi K; Yang Y; Lin D
Mod Pathol; 2021 Nov; 34(11):1990-1998. PubMed ID: 34253867
[TBL] [Abstract][Full Text] [Related]
2. "Percentage" and "size" of residual viable tumor in lymph node, the performance in estimating pathologic response of lymph node in non-small cell lung cancer treated with neoadjuvant chemoimmunotherapy.
Sun W; Qu L; Wu J; Liu X; Wang C; Jiang Y; Liu Y; Chen M; Wang X; Lin D
Hum Pathol; 2024 May; 149():1-9. PubMed ID: 38782102
[TBL] [Abstract][Full Text] [Related]
3. The prognostic value of ratio-based lymph node staging in resected non-small-cell lung cancer.
Qiu C; Dong W; Su B; Liu Q; Du J
J Thorac Oncol; 2013 Apr; 8(4):429-35. PubMed ID: 23486264
[TBL] [Abstract][Full Text] [Related]
4. [Remission rate of mediastinal lymph nodes after multimodal therapy of lung cancer--is it a prognostic factor?].
Granetzny A; Striehn E; Bosse U; Wagner W; Koch O; Vogt U; Froeschle P; Klinke F
Zentralbl Chir; 2003 Aug; 128(8):640-4. PubMed ID: 12931258
[TBL] [Abstract][Full Text] [Related]
5. A prognostic score for non-small cell lung cancer resected after neoadjuvant therapy in comparison with the tumor-node-metastases classification and major pathological response.
Zens P; Bello C; Scherz A; Koenigsdorf J; Pöllinger A; Schmid RA; Ochsenbein A; Neppl C; Langer R; Berezowska S
Mod Pathol; 2021 Jul; 34(7):1333-1344. PubMed ID: 33714982
[TBL] [Abstract][Full Text] [Related]
6. Characterizing the impact of lymph node metastases on the survival outcome for metastatic renal cell carcinoma patients treated with targeted therapies.
Kroeger N; Pantuck AJ; Wells JC; Lawrence N; Broom R; Kim JJ; Srinivas S; Yim J; Bjarnason GA; Templeton A; Knox J; Bernstein E; Smoragiewicz M; Lee J; Rini BI; Vaishampayan UN; Wood LA; Beuselinck B; Donskov F; Choueiri TK; Heng DY
Eur Urol; 2015 Sep; 68(3):506-15. PubMed ID: 25524810
[TBL] [Abstract][Full Text] [Related]
7. Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy.
Pataer A; Kalhor N; Correa AM; Raso MG; Erasmus JJ; Kim ES; Behrens C; Lee JJ; Roth JA; Stewart DJ; Vaporciyan AA; Wistuba II; Swisher SG;
J Thorac Oncol; 2012 May; 7(5):825-32. PubMed ID: 22481232
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Impact of Node-Spreading Pattern in Surgically Treated Small-Cell Lung Cancer: A Multicentric Analysis.
Leuzzi G; Lococo F; Alessandrini G; Sperduti I; Spaggiari L; Venuta F; Rendina EA; Granone PM; Rapicetta C; Zannini P; Di Rienzo G; Nicolosi M; Facciolo F
Lung; 2017 Feb; 195(1):107-114. PubMed ID: 27738827
[TBL] [Abstract][Full Text] [Related]
9. Analysis of the T descriptors and other prognosis factors in pathologic stage I non-small cell lung cancer in China.
Li Z; Yu Y; Lu J; Luo Q; Wu C; Liao M; Zheng Y; Ai X; Gu L; Lu S
J Thorac Oncol; 2009 Jun; 4(6):702-9. PubMed ID: 19404215
[TBL] [Abstract][Full Text] [Related]
10. Effects of neoadjuvant chemotherapy on primary tumor and lymph node metastasis in esophageal squamous cell carcinoma: additive association with prognosis.
Akita H; Doki Y; Yano M; Miyata H; Miyashiro I; Ohigashi H; Ishikawa O; Nishiyama A; Imaoka S
Dis Esophagus; 2009; 22(4):291-7. PubMed ID: 19021686
[TBL] [Abstract][Full Text] [Related]
11. [Postoperative survival analysis of patients with stage Ⅲ-pN2 non-small cell lung cancer].
Wu XW; Chen T; Yin S; Deng Y; Zhao B
Zhonghua Zhong Liu Za Zhi; 2018 Oct; 40(10):782-786. PubMed ID: 30392344
[No Abstract] [Full Text] [Related]
12. Pathologic Assessment After Neoadjuvant Chemotherapy for NSCLC: Importance and Implications of Distinguishing Adenocarcinoma From Squamous Cell Carcinoma.
Qu Y; Emoto K; Eguchi T; Aly RG; Zheng H; Chaft JE; Tan KS; Jones DR; Kris MG; Adusumilli PS; Travis WD
J Thorac Oncol; 2019 Mar; 14(3):482-493. PubMed ID: 30503889
[TBL] [Abstract][Full Text] [Related]
13. Radical systematic mediastinal lymphadenectomy versus mediastinal lymph node sampling in patients with clinical stage IA and pathological stage T1 non-small cell lung cancer.
Ma K; Chang D; He B; Gong M; Tian F; Hu X; Ji Z; Wang T
J Cancer Res Clin Oncol; 2008 Dec; 134(12):1289-95. PubMed ID: 18504610
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Significance of the Number of Metastatic pN2 Lymph Nodes in Stage IIIA-N2 Non-Small-Cell Lung Cancer After Curative Resection.
Yoo C; Yoon S; Lee DH; Park SI; Kim DK; Kim YH; Kim HR; Choi SH; Kim WS; Choi CM; Jang SJ; Song SY; Kim SS; Choi EK; Lee JC; Suh C; Lee JS; Kim SW
Clin Lung Cancer; 2015 Nov; 16(6):e203-12. PubMed ID: 25997733
[TBL] [Abstract][Full Text] [Related]
15. Pathologic Processing of Lung Cancer Resection Specimens After Neoadjuvant Therapy.
Weissferdt A; Leung CH; Lin H; Sepesi B; William WN; Swisher SG; Cascone T; Lee JJ; Pataer A
Mod Pathol; 2024 Jan; 37(1):100353. PubMed ID: 37844869
[TBL] [Abstract][Full Text] [Related]
16. Mediastinal Up-Staging During Surgery in Non-Small-Cell Lung Cancer: Which Mediastinal Lymph Node Metastasis Patterns Better Predict The Outcome? A Multicenter Analysis.
Chiappetta M; Leuzzi G; Sperduti I; Bria E; Mucilli F; Lococo F; Filosso PL; Ratto GB; Spaggiari L; Facciolo F
Clin Lung Cancer; 2020 Sep; 21(5):464-471.e1. PubMed ID: 32389508
[TBL] [Abstract][Full Text] [Related]
17. "Major pathologic response" in lymph nodes: a modified nodal classification for non-small cell lung cancer patients treated with neoadjuvant immunochemotherapy.
Deng H; Xiong S; Zhong R; Zheng Y; Liang H; Cheng B; Li J; Li F; Chen Z; Wang H; He J; Liang W
Exp Hematol Oncol; 2023 Apr; 12(1):40. PubMed ID: 37072866
[TBL] [Abstract][Full Text] [Related]
18. Association of lymph node involvement with the prognosis of pathological T1 invasive non-small cell lung cancer.
Zhang YK; Chai ZD; Tan LL; Wang ZY; Chen ZJ; Le HB; Zhu WY
World J Surg Oncol; 2017 Mar; 15(1):64. PubMed ID: 28302176
[TBL] [Abstract][Full Text] [Related]
19. Pretreatment clinical mediastinal nodal bulk and extent do not influence survival in N2-positive stage IIIA non-small cell lung cancer patients treated with trimodality therapy.
Lee H; Ahn YC; Pyo H; Kim B; Oh D; Nam H; Lee E; Sun JM; Ahn JS; Ahn MJ; Park K; Choi YS; Kim J; Zo JI; Shim YM
Ann Surg Oncol; 2014 Jun; 21(6):2083-90. PubMed ID: 24522994
[TBL] [Abstract][Full Text] [Related]
20. Major pathological response exhibited distinct prognostic significance for lung adenocarcinoma post different modalities of neoadjuvant therapy.
Xia L; Guo J; E H; Zhang W; Huang Y; Zhang L; Zhao D; Xie D; Wu C; Hou L
Histopathology; 2023 Apr; 82(5):691-703. PubMed ID: 36579364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
